Fertility preservation and reproductive health in the pediatric, adolescent, and young adult female cancer patient

Current Opinion in Obstetrics and Gynecology

Volumn 26, Issue 5, 2014, Pages 372-380

  Trudgen, Kourtney ^a   Ayensu Coker, Leslie ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Antimullerian hormone; Fertility; Gonadotoxicity; Ovarian reserve

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; MUELLERIAN INHIBITING FACTOR;

ADOLESCENT; ADULT; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CRYOPRESERVATION; FEMALE FERTILITY; FEMALE INFERTILITY; FERTILITY PRESERVATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; OVARY; OVARY HYPERSTIMULATION; OVARY INSUFFICIENCY; PRIORITY JOURNAL; PUBERTAL ARREST; PUBERTY DISORDERS; QUALITY OF LIFE; REPRODUCTIVE HEALTH; REVIEW; STIMULATION; YOUNG ADULT; ADJUVANT THERAPY; ADVERSE EFFECTS; COMPLICATION; FEMALE; INFERTILITY THERAPY; INFERTILITY, FEMALE; NEOPLASMS; OOCYTE RETRIEVAL; OVULATION INDUCTION; PROCEDURES; SURVIVOR;

ADOLESCENT; ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS; CHILD; CRYOPRESERVATION; FEMALE; FERTILITY PRESERVATION; HUMANS; INFERTILITY, FEMALE; NEOPLASMS; OOCYTE RETRIEVAL; OVULATION INDUCTION; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; REPRODUCTIVE HEALTH; REPRODUCTIVE TECHNIQUES; SURVIVORS; YOUNG ADULT;

EID: 84925742328     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000107     Document Type: Review

References (65)

1. American Cancer Society. Cancer facts & figures. Atlanta, GA; 2014.
2. Pui CH, Gajjar AJ, Kane JR, et al. Challenging issues in pediatric oncology. Nat Rev Clin Oncol 2011;8:540-549.
3. Armenian SH, Robison LL. Childhood cancer survivorship: an update on evolving paradigms for understanding pathogenesis and screening for therapy-related late effects. Curr Opin Pediatr 2013;25:16-22. This study details the late effect of gonadotoxic agents on fertility. This is of clinical importance in that it illustrates the degree of infertility after treatment and emphasizes the importance of addressing fertility preservation prior to treatment.
4. Metzger ML, Meacham LR, Patterson B, et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol 2013;31:1239-1247.
5. Armuand GM, Wettergren L, Rodriguez-Wallberg KA, Lampic C. Desire for children, difficulties achieving a pregnancy, and infertility distress 3 to 7 years after cancer diagnosis. Support Care Cancer 2014. doi: 10.1007/s00520-014-2279-z. [Epub ahead of print] http://link.springer.com/article/10.1007/s00520-014-2279-z/fulltext.html.
6. Greaves P, Sarker SJ, Chowdhury K, et al. Fertility and sexual function in longterm survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. Br J Haematol 2014;164:526-535.
7. Wilson DB, Link DC, Mason PJ, Bessler M. Inherited bone marrow failure syndromes in adolescents and young adults. Ann Med 2014;1-11. doi:10.3109/07853890.2014.915579. [Epub ahead of print] http://informahealthcare.com/doi/abs/10.3109/07853890.2014.915579.
8. Mitchell R, Nivison-Smith I, Anazodo A, et al. Outcomes of haematopoietic stem cell transplantation for inherited metabolic disorders: a report from the Australian and New Zealand Children's Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry. Pediatr Transplant 2013;17:582-588.
9. Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril 2005;83:1622-1628.
10. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500-2510. This study details the current guidelines for fertility preservation counseling. It is of significance because it guides the clinician and establishes the standard of care in fertility preservation in oncology patients.
11. Bashore L, Carr B, Lockart B, Schmidt D, Stegenga K: APHON Position Paper on Fertility Preservation for Pediatric and Adolescent Young Adult (AYA) Cancer Patients. August 2012,. http://www.aphon.org/files/members/onco-fertilitydraft.pdf. Accessed July 16, 2014.
12. Institute NC. PDQ1 Unusual cancers of childhood treatment: Bethesda, MD: National Cancer Institute; 2005-2009 [updated 4 April 2013]. Available from: http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthProfessional. [Accessed 27 June 2014]
13. Institute NC. A snapshot of adolescent and young adult cancers: Bethesda, MD: National Cancer Institute; 2013 [updated 2 December 2013]. Available from: http://www.cancer.gov/researchandfunding/snapshots/adolescentyoungadult. [Accessed 28 June 2014]
14. Howlader N, Noone AM, Krapcho M, et al. Childhood cancer by the ICCC. SEER cancer statistics review, 1975-2009 (Vintage 2009 Populations): Bethesda, MD: National Cancer Institute; 2012, Section 29. Also available online. [Accessed 29 January 2014]
15. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer statistics review, 1975-2011: Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975-2011/, based on November 2013 SEER data submission, posted to the SEER website. [Accessed April 2014]
16. Bleyer A, Barr R, Hayes-Lattin B, et al. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 2008;8:288-298.
17. Grigsby TJ, Kent EE, Montoya MJ, et al. Attitudes toward cancer clinical trial participation in young adults with a history of cancer and a healthy college student sample: a preliminary investigation. J Adolesc Young Adult Oncol 2014;3:20-27.
18. Papic JC, Finnell SM, Slaven JE, et al. Predictors of ovarian malignancy in children: overcoming clinical barriers of ovarian preservation. J Pediatr Surg 2014;49:144-147.
19. Kort JD, Eisenberg ML, Millheiser LS, Westphal LM. Fertility issues in cancer survivorship. CA Cancer J Clin 2014;64:118-134.
20. Children's Oncology group. Long term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, Version 3.0. Arcadia, Ca: Children's Oncology Group; October 2008; Available at: www.survivorship guidelines.org.
21. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931.
22. Harward LE, Mitchell K, Pieper C, et al. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus 2013;22:81-86.
23. Salooja N, Szydlo RM, Socie G, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001;358:271-276.
24. Nakayama K, Milbourne A, Schover LR, et al. Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. Nat Clin Pract Oncol 2008;5:78-89.
25. Zhou L, Xu N, Sun Y, Liu XM. Targeted biopharmaceuticals for cancer treatment. Cancer Lett 2014. doi: 10.1016/j.canlet.2014.06.020. [Epub ahead of print] http://www.cancerletters.info/article/S0304-3835 (14) 00336-X/fulltext.
26. Lodish MB. Clinical review: kinase inhibitors: adverse effects related to the endocrine system. J Clin Endocrinol Metab 2013;98:1333-1342.
27. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-816.
28. Eisengart JB, Rudser KD, Tolar J, et al. Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J Pediatr 2013;162:375-380.
29. Bondy CA; Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007;92:10-25.
30. Peigne M, Decanter C. Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. Reprod Biol Endocrinol 2014;12:1-10. This study summarizes the role of AMH as a better marker of ovarian reserve after gonadotoxic therapy than FSH and return of menstrual function. It is of importance because it supports AMH as the most reliable marker of ovarian reserve in oncology patients.
31. Anderson RA, Wallace WH. Antimullerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertil Steril 2013;99:1469-1475. This study describes the role of AMH in the assessment of ovarian reserve in young oncology patients. It is clinically important because of the need to identify patients at greatest risk for fertility compromise from therapy.
32. Malheiro OB, Rezende CP, Rocha AL, et al. Regular menstrual cycles do not rule out ovarian damage in adult women with systemic lupus erythematosus. Gynecol Endocrinol 2014;1-4. doi:10.3109/09513590.2014.922949; http://informahealthcare.com/doi/abs/10.3109/09513590.2014.922949.
33. Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimullerian hormone. Fertil Steril 2013;99:1825-1830.
34. Monniaux D, Clement F, Dalbies-Tran R, et al. The ovarian reserve of primordial follicles and the dynamic reserve of antral growing follicles: what is the link? Biol Reprod 2014;90:1-11.
35. Scheffer GJ, Broekmans FJ, Looman CW, et al. The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum Reprod 2003;18:700-706.
36. Lunsford AJ, Whelan K, McCormick K, McLaren JF. Antimullerian hormone as a measure of reproductive function in female childhood cancer survivors. Fertil Steril 2014;101:227-231. This study describes the mechanism of action of AMH and its roles as a marker of reproductive function in cancer survivors. It is of clinical importance, as it becomes a tool for identifying patients at greatest risk of fertility compromise after therapy.
37. Seifer DB, Baker VL, Leader B. Age-specific serum anti-Mullerian hormone values for 17, 120 women presenting to fertility centers within the United States. Fertil Steril 2011;95:747-750.
38. Ruddy KJ, O'Neill A, Miller KD, et al. Biomarker prediction of chemotherapyrelated amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat 2014;144:591-597.
39. Ledger WL. Measurement of antimullerian hormone: not as straightforward as it seems. Fertil Steril 2014;101:339. This study details the difficulties with previous AMH assays as well as the advancements with the current assay. This is of clinical importance as it cautions providers to use care in interpreting AMH levels.
40. Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 2014;20:370-385.
41. Konc J, Kanyo K, Kriston R, et al. Cryopreservation of embryos and oocytes in human assisted reproduction. Biomed Res Int 2014;2014:1-9.
42. Practice Committees of American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril 2013;99:37-43. This study describes the science behind establishing mature oocyte freezing as a standard reproductive technology. This is of clinical importance as it provides an important option for patients.
43. Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril 2013;100:1673-1680.
44. Brambillasca F, Guglielmo MC, Coticchio G, et al. The current challenges to efficient immature oocyte cryopreservation. J Assist Reprod Genet 2013;30:1531-1539.
45. Fadini R, Mignini Renzini M, Dal Canto M, et al. Oocyte in vitro maturation in normo-ovulatory women. Fertil Steril 2013;99:1162-1169.
46. Meirow D, Ra'anani H, Biderman H. Ovarian tissue cryopreservation and transplantation: a realistic, effective technology for fertility preservation. Methods Mol Biol 2014;1154:455-473. This study details the feasibility of ovarian tissue cryopreservation in producing life births. It is of clinical importance in that it provides an option for prepubertal patients and patientswhocannot undergo ovarian stimulation. The studymoves ovarian tissue cryopreservation one step further to becoming a standard option for patients.
47. Donnez J, Dolmans MM. Fertility preservation in women. Nat Rev Endocrinol 2013;9:735-749. This study is important in that it details the successes of ovarian tissue cryopreservation and emphasizes the importance of moving this technology toward becoming standard of care in high risk patients.
48. Kilic S, Pinarli F, Ozogul C, et al. Protection from cyclophosphamide-induced ovarian damage with bone marrow-derived mesenchymal stem cells during puberty. Gynecol Endocrinol 2014;30:135-140.
49. Wang C, Chen M, Fu F, Huang M. Gonadotropin-releasing hormone analog cotreatment for the preservation of ovarian function during gonadotoxic chemotherapy for breast cancer: a meta-analysis. PLoS One 2013;8:1-7.
50. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011; CD008018.
51. Del Mastro L, Ceppi M, Poggio F, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev 2014;40:675-683.
52. Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013;121:78-86.
53. Demeestere I, Brice P, Peccatori FA, et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 2013;31:903-909.
54. Adegite EA, Goyal RK, Murray PJ, et al. The management of menstrual suppression and uterine bleeding: a survey of current practices in the Pediatric Blood and Marrow Transplant Consortium. Pediatr Blood Cancer 2012;59:553-557.
55. Bates JS, Buie LW, Woodis CB. Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. Pharmacotherapy 2011;31:1092-1110.
56. Wang S, Yu L, Sun M, et al. The therapeutic potential of umbilical cord mesenchymal stem cells in mice premature ovarian failure. Biomed Res Int 2013;2013:1-12.
57. Skaznik-Wikiel ME, McGuire MM, Sukhwani M, et al. Granulocyte colonystimulating factor with or without stem cell factor extends time to premature ovarian insufficiency in female mice treated with alkylating chemotherapy. Fertil Steril 2013;99:2045-2054.
58. Zebrack BJ, Casillas J, Nohr L, et al. Fertility issues for young adult survivors of childhood cancer. Psychooncology 2004;13:689-699.
59. Assouline E, Crocchiolo R, Prebet T, et al. Impact of reduced-intensity conditioning allogeneic stem cell transplantation on women's fertility. Clin Lymphoma Myeloma Leuk 2013;13:704-710.
60. Louwe LA, Ter Kuile MM, Hilders CG, et al. Oncologists' practice and attitudes regarding fertility preservation in female cancer patients: a pilot study in the Netherlands. J Psychosom Obstet Gynaecol 2013;34:129-132.
61. Forman EJ, Anders CK, Behera MA. A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients. Fertil Steril 2010;94:1652-1656.
62. Mersereau JE, Goodman LR, Deal AM, et al. To preserve or not to preserve: how difficult is the decision about fertility preservation? Cancer 2013;119:4044-4050. This study described the difficulties patients face in making a decision about fertility preservation options. It is of importance because it illustrates barriers that need to be overcome in order to provide optimal care to patients.
63. ASRM. Infertility, reproduction, menopause, andrology, endometriosis, diagnosis and treatment. State infertility insurance laws. Available from: http://www.asrm.org/insurance.aspx. [Accessed 28 June 2014]
64. Ayensu-Coker L, Bauman D, Lindheim SR, Breech L. Fertility preservation in pediatric, adolescent and young adult female cancer patients. Pediatr Endocrinol Rev 2012;10:174-187.
65. Ayensu-Coker L, Essig E, Breech LL, Lindheim S. Ethical quandaries in gamete-embryo cryopreservation related to oncofertility. J Law Med Ethics 2013;41:711-719.